Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostic & Research Stocks to Buy Now (2025)

Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

Sotera Health Co (NASDAQ:SHC) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 24, which is -2 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 8 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock lose -0.95% over the past year, underperforming other diagnostic & research stocks by -7 percentage points.

Sotera Health Co has an average 1 year price target of $17.67, an upside of 12.67% from Sotera Health Co's current stock price of $15.68.

Sotera Health Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Sotera Health Co, 33.33% have issued a Strong Buy rating, 0% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Idexx Laboratories (NASDAQ:IDXX) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: A, and AI: B.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 50, which is 24 points higher than the diagnostic & research industry average of 26.

IDXX passed 17 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 63.61% over the past year, overperforming other diagnostic & research stocks by 57 percentage points.

Idexx Laboratories has an average 1 year price target of $737.14, an upside of 4.05% from Idexx Laboratories's current stock price of $708.45.

Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Idexx Laboratories, 57.14% have issued a Strong Buy rating, 14.29% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Agilent Technologies (NYSE:A) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Agilent Technologies (NYSE:A) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: B, and AI: C.

Agilent Technologies (NYSE:A) has a Due Diligence Score of 41, which is 15 points higher than the diagnostic & research industry average of 26.

A passed 15 out of 38 due diligence checks and has strong fundamentals. Agilent Technologies has seen its stock return 5.09% over the past year, underperforming other diagnostic & research stocks by -1 percentage points.

Agilent Technologies has an average 1 year price target of $152.90, an upside of 4.2% from Agilent Technologies's current stock price of $146.74.

Agilent Technologies stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Agilent Technologies, 60% have issued a Strong Buy rating, 10% have issued a Buy, 30% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.34%, which is 1 percentage points higher than the diagnostic & research industry average of 0.66%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 27.2% indicates that its dividend yield is sustainable for the long-term.

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.14%, which is the same as the diagnostic & research industry average of 0.66%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 28.1% indicates that its dividend yield is sustainable for the long-term.

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.51%, which is the same as the diagnostic & research industry average of 0.66%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22.9% indicates that its dividend yield is sustainable for the long-term.

Diagnostic & research stocks were up 0.09% in the last day, and up 1.29% over the last week. Natera was the among the top gainers in the diagnostics & research industry, gaining 0.55% yesterday.

NTRA stock has given up its prior gain. Natera shares were trading higher after the company reported better-than-expected Q3 sales results and raised its FY25 sales guidance above estimates.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 43, which is 28 points higher than the diagnostic & research industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Qiagen Nv's stock has dropped -1.34% in the past year. It has underperformed other stocks in the diagnostic & research industry by -8 percentage points.

Icon (NASDAQ:ICLR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 42 points higher than the diagnostic & research industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -25.98% in the past year. It has underperformed other stocks in the diagnostic & research industry by -32 percentage points.

Revvity (NYSE:RVTY) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Revvity has a valuation score of 14, which is -1 points higher than the diagnostic & research industry average of 15. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates RVTY a Valuation Rating of "B".

Revvity's stock has dropped -26.79% in the past year. It has underperformed other stocks in the diagnostic & research industry by -33 percentage points.

65.85% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 5.04% over the next year.

2.22% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 24.44% of diagnostic & research stocks are rated B (Buy), 62.22% are rated C (Hold), 4.44% are rated D (Sell), and 6.67% are rated F (Strong Sell).